Clarity Pharmaceuticals Ltd

ASX:CU6 Stock Report

Market Cap: AU$2.1b

Clarity Pharmaceuticals Management

Management criteria checks 3/4

Clarity Pharmaceuticals' CEO is Colin Biggin, appointed in Oct 2019, has a tenure of 4.83 years. total yearly compensation is A$1.02M, comprised of 43.5% salary and 56.5% bonuses, including company stock and options. directly owns 1.03% of the company’s shares, worth A$21.84M. The average tenure of the management team and the board of directors is 4.8 years and 4.6 years respectively.

Key information

Colin Biggin

Chief executive officer

AU$1.0m

Total compensation

CEO salary percentage43.5%
CEO tenure4.8yrs
CEO ownership1.0%
Management average tenure4.8yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

CEO Compensation Analysis

How has Colin Biggin's remuneration changed compared to Clarity Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-AU$42m

Mar 31 2024n/an/a

-AU$36m

Dec 31 2023n/an/a

-AU$31m

Sep 30 2023n/an/a

-AU$28m

Jun 30 2023AU$1mAU$444k

-AU$25m

Mar 31 2023n/an/a

-AU$23m

Dec 31 2022n/an/a

-AU$21m

Sep 30 2022n/an/a

-AU$23m

Jun 30 2022AU$811kAU$347k

-AU$24m

Mar 31 2022n/an/a

-AU$21m

Dec 31 2021n/an/a

-AU$19m

Sep 30 2021n/an/a

-AU$15m

Jun 30 2021AU$907kAU$308k

-AU$10m

Mar 31 2021n/an/a

-AU$9m

Dec 31 2020n/an/a

-AU$9m

Sep 30 2020n/an/a

-AU$8m

Jun 30 2020AU$657kAU$303k

-AU$7m

Compensation vs Market: Colin's total compensation ($USD686.86K) is below average for companies of similar size in the Australian market ($USD1.37M).

Compensation vs Earnings: Colin's compensation has increased whilst the company is unprofitable.

CEO

Colin Biggin

4.8yrs

Tenure

AU$1,020,674

Compensation

Dr. Colin David Biggin, Ph D., has been Managing Director, Chief Executive Officer and Executive Director at Clarity Pharmaceuticals Ltd since October 1, 2019. Dr. Biggin joined Clarity Pharmaceuticals Pty...

Leadership Team

NamePositionTenureCompensationOwnership
Alan Taylor
Executive Chairman10.8yrsAU$1.22m4.63%
A$ 98.2m
Colin Biggin
MD, CEO & Executive Director4.8yrsAU$1.02m1.03%
A$ 21.8m
David Green
Chief Financial Officer2.3yrsAU$273.61kno data
Shaemus Gleason
Executive Vice President of Operationsno datano datano data
Matthew Harris
Chief Scientific Officerno dataAU$241.43k1.92%
A$ 40.8m
Lisa Sadetskaya
Director of Corporate Communications.no datano datano data
Mary Bennett
Head of Human Resourceno datano datano data
Michelle Parker
Chief Clinical Officerno datano datano data
Othon Gervasio
Chief Medical Officerno datano datano data
Robert Vickery
Company Secretaryno dataAU$268.69kno data

4.8yrs

Average Tenure

Experienced Management: CU6's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alan Taylor
Executive Chairman10.8yrsAU$1.22m4.63%
A$ 98.2m
Colin Biggin
MD, CEO & Executive Director4.8yrsAU$1.02m1.03%
A$ 21.8m
Christopher Roberts
Non-Executive Director8.4yrsAU$86.88k5.68%
A$ 120.4m
Thomas Ramdahl
Non-Executive Director5.4yrsAU$86.88k0.16%
A$ 3.5m
Robert Thomas
Lead Independent Director3yrsAU$79.56k0.37%
A$ 7.9m
Neal Shore
Member of Scientific Advisory Board2.3yrsno datano data
Rosanne Robinson
Independent Non-Executive Director13.8yrsAU$95.72kno data
Jason Lewis
Member of Scientific Advisory Boardno datano datano data
Oliver Sartor
Member of Scientific Advisory Board4.4yrsno datano data
Paul Donnelly
Member of Scientific Advisory Boardno datano datano data
Andrei Iagaru
Member of Scientific Advisory Board2.3yrsno datano data
Louise Emmett
Member of Scientific Advisory Board2.2yrsno datano data

4.6yrs

Average Tenure

70yo

Average Age

Experienced Board: CU6's board of directors are considered experienced (4.6 years average tenure).